既往HIV-1已抑制者使用多替拉韦/拉米夫定出现整合酶耐药
本文报告一例长期HIV-1病毒血症抑制(<50拷贝/mL)、无已知病毒学失败危险因素且既往未暴露于整合酶抑制剂的感染者,在换用多替拉韦/拉米夫定后出现病毒学失败(连续血浆HIV-1 RNA 149和272拷贝/mL,CD4细胞322个/mm3),深度测序检出整合酶R263K(79.6%)和S230N(99.4%)突变,提示整合酶耐药可在该方案治疗中产生,需警惕药物相互作用。
要点
- 多替拉韦/拉米夫定治疗中可出现整合酶关键突变R263K导致病毒学失败。
- 患者同时使用氯巴占,原文认为其与多替拉韦潜在弱相互作用、不太可能需要调整剂量。
- 即使药物相互作用潜力被认为较低,使用多替拉韦/拉米夫定者也需仔细考虑和监测。
核心结论
- 本病例表明整合酶耐药可在接受多替拉韦/拉米夫定复方制剂治疗的患者中出现,并提示对使用该方案者即使药物相互作用潜力被认为较低也需仔细考虑和监测。
研究设计与样本
- 临床病例报告。
主要发现
- 患者长期HIV-1病毒血症抑制(<50拷贝/mL),无已知病毒学失败危险因素,既往从未暴露于整合酶抑制剂,治疗依从性良好,仍出现病毒学失败:连续血浆HIV-1 RNA 149和272拷贝/mL,CD4细胞322个/mm3。
- 患者当时正在使用抗惊厥药氯巴占,原文认为其与多替拉韦有潜在弱相互作用,不太可能需要调整剂量。
- 血浆HIV-1基因型深度测序(Vela系统)显示整合酶区出现R263K(79.6%)和S230N(99.4%)突变,对多替拉韦为中度耐药(Stanford HIVDB 9.0评分=30)。
- 因病毒载量低,逆转录酶区和蛋白酶区无法扩增。
- 数月后PBMC DNA深度测序显示逆转录酶区M184I(14.29%)和M230I(6.25%),整合酶区G163R(9.77%)和S230N(98.8%);R263K仅以极低水平(0.07%)检出。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Integrase resistance has not been reported with co-formulated dolutegravir/lamivudine in clinical trials or real-life cohorts. We aim to report, to the best of our knowledge, the first case of selection of the key integrase mutation R263K in a subject treated with this regimen started as a switch strategy with undetectable plasma HIV-1 viraemia. METHODS: Clinical case report. RESULTS: A patient with long-term suppressed HIV-1 viraemia (<50 copies/mL) with no known risk factors for virological failure and never exposed previously to an integrase inhibitor developed virological failure (consecutive plasma HIV-1 RNA 149 and 272 copies/mL) with 322 CD4 cells/mm3 despite good treatment adherence. He was receiving the anticonvulsant clobazam, considered to have a potential weak interaction with dolutegravir, unlikely to require a dose adjustment. Plasma HIV-1 genotypic deep sequencing (Vela System) revealed the emergence of R263K (79.6%) and S230N (99.4%) mutations in the integrase region (intermediate resistance to dolutegravir, score = 30 Stanford HIVDB 9.0). The reverse transcriptase and protease regions could not be amplified due to low viral loads. PBMC DNA deep sequencing performed some months later revealed mutations M184I (14.29%) and M230I (6.25%) in the reverse transcriptase and G163R (9.77%) and S230N (98.8%) in the integrase. R263K was only found at extremely low levels (0.07%). CONCLUSIONS: This case illustrates that integrase resistance can emerge in patients treated with co-formulated dolutegravir/lamivudine and raises awareness of the need to carefully consider and monitor drug-drug interactions, even when regarded as having a low potential, in subjects treated with dolutegravir/lamivudine.
引用
- Revollo B, Viñuela L, de la Mora L, et al. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression. J Antimicrob Chemother. 2022. PMID: 35274144. doi:10.1093/jac/dkac082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。